Gossamer Bio (GOSS) to Release Earnings on Thursday

Gossamer Bio (NASDAQ:GOSS) is expected to be releasing its Q4 2025 results before the market opens on Thursday, March 12th. Analysts expect Gossamer Bio to post earnings of ($0.19) per share and revenue of $7.5260 million for the quarter. Parties can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Wednesday, March 11, 2026 at 4:00 PM ET.

Gossamer Bio Stock Performance

Shares of Gossamer Bio stock opened at $0.58 on Thursday. The company has a market cap of $134.25 million, a P/E ratio of -0.84 and a beta of 2.08. Gossamer Bio has a fifty-two week low of $0.33 and a fifty-two week high of $3.87. The firm has a 50-day simple moving average of $2.23 and a two-hundred day simple moving average of $2.60.

Institutional Investors Weigh In On Gossamer Bio

A number of hedge funds have recently modified their holdings of the company. Invesco Ltd. raised its position in shares of Gossamer Bio by 36.0% during the 4th quarter. Invesco Ltd. now owns 478,909 shares of the company’s stock valued at $1,485,000 after buying an additional 126,823 shares during the period. Corient Private Wealth LLC boosted its stake in Gossamer Bio by 19,123.7% during the fourth quarter. Corient Private Wealth LLC now owns 3,845,885 shares of the company’s stock worth $11,922,000 after buying an additional 3,825,879 shares during the period. Mercer Global Advisors Inc. ADV raised its stake in shares of Gossamer Bio by 52.3% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 23,983 shares of the company’s stock valued at $74,000 after acquiring an additional 8,239 shares during the period. Beacon Pointe Advisors LLC acquired a new position in shares of Gossamer Bio in the 4th quarter worth approximately $34,000. Finally, XTX Topco Ltd boosted its position in shares of Gossamer Bio by 66.1% during the 4th quarter. XTX Topco Ltd now owns 456,329 shares of the company’s stock worth $1,415,000 after purchasing an additional 181,547 shares during the period. Hedge funds and other institutional investors own 81.23% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on GOSS shares. Wall Street Zen cut Gossamer Bio from a “hold” rating to a “sell” rating in a research report on Friday, January 23rd. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Gossamer Bio in a research note on Thursday, January 22nd. Barclays lowered shares of Gossamer Bio from an “overweight” rating to an “underweight” rating in a report on Tuesday, February 24th. Weiss Ratings restated a “sell (d-)” rating on shares of Gossamer Bio in a research report on Thursday, January 22nd. Finally, Royal Bank Of Canada upgraded shares of Gossamer Bio to an “outperform” rating in a research report on Tuesday, February 24th. Four research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Gossamer Bio presently has a consensus rating of “Hold” and a consensus target price of $6.67.

About Gossamer Bio

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.